UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017770
Receipt number R000020584
Scientific Title The influence of GLP-1 receptor agonist on the heart rate using holter electrocardiography and power spectrum analysis on heart rate variability
Date of disclosure of the study information 2015/06/02
Last modified on 2015/06/02 15:41:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The influence of GLP-1 receptor agonist on the heart rate using holter electrocardiography and power spectrum analysis on heart rate variability

Acronym

The influence of GLP-1 receptor agonist on the heart rate

Scientific Title

The influence of GLP-1 receptor agonist on the heart rate using holter electrocardiography and power spectrum analysis on heart rate variability

Scientific Title:Acronym

The influence of GLP-1 receptor agonist on the heart rate

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Cardiology Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Several studies have reported that GLP-1 receptor agonists (GLP-1RA) increase the heart rate, but no study on the difference between long- and short-acting GLP-1RA has been reported. We performed Holter electrocardiography and power spectrum analysis of heart rate variability before and after the administration of a long-acting GLP-1RA, Liraglutide, and a short-acting GLP-1RA, Lixisenatide, and compared the influences on the heart rate and autonomic nervous system between the 2 drugs.

Basic objectives2

Pharmacodynamics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

24h-heart rate
Holter electrocardiograph
Power spectrum analysis
before or after 2h meal and night time glucose

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Liraglutide group

Interventions/Control_2

Lixisenatide group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

patient with type 2 DM doing a hospitalizing for diabetes

Patients with no history of treatment to GLP-1 or DDP-4 inhibitor

Key exclusion criteria

Type 1 DM
history of arrythmia
Severe diabetic neuropathy
history of pancreatitis
Pregnancy

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nakatai Yuki

Organization

Dokkyomedical university nikko medical center

Division name

Diabates and endcrinology

Zip code


Address

632 takatoku,nikkoshi,tochigi

TEL

0288-76-1515

Email

yu-naka@dokkyomed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nakatani Yuki

Organization

Dokkyomedical university nikko medical center

Division name

Diabates and endcrinology

Zip code


Address

632 takatoku,nikkoshi,tochigi

TEL

0288-76-1515

Homepage URL


Email

yu-naka@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyomedical university nikko medical center

Institute

Department

Personal name



Funding Source

Organization

Dokkyomedical university nikko medical center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

獨協医科大学日光医療センター


Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 02 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2014 Year 04 Month 01 Day

Last follow-up date

2015 Year 04 Month 30 Day

Date of closure to data entry

2015 Year 05 Month 31 Day

Date trial data considered complete

2015 Year 05 Month 31 Day

Date analysis concluded

2015 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 06 Month 02 Day

Last modified on

2015 Year 06 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020584


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name